Anti-IL-23 antibodies, compositions, methods and uses

• US 7,807,414 B2
• Filed: 02/13/2009
• Issued: 10/05/2010
• Est. Priority Date: 06/30/2005
• Status: Active Grant

• Current Assignee: Janssen Biotech, Inc. (Johnson & Johnson)
• Original Assignee: Centocor Ortho Biotech Incorporated (Johnson & Johnson)
• Inventors: Giles-Komar, Jill M., Raymond, Sweet, Luo, Jinquan, Rycyzyn, Michael A., Cunningham, Mark, Duchala, Cynthia, Benson, Jacqueline
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US12/370,872
• Publication Number:
  US 20090162371A1
• Time in Patent Office: 599 Days
• Field of Search: None
• US Class Current: 435/69.6
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/55527 Interleukins
• CPC Class Codes: A61K 2039/55544 Bacterial toxins
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 for peripheral neuropathies
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 2317/30 characterized by aspects of specificity or valency
• CPC Class Codes: C07K 2317/33 : Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 : Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/56 : variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 : Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: C07K 2319/55 : containing a fusion with a toxin, e.g. diphteria toxin
• CPC Class Codes: G01N 2333/54 : Interleukins [IL]
• CPC Class Codes: G01N 33/6869 : Interleukin
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Claims

1. An isolated nucleic acid molecule encoding an IL-23p19 antibody capable of binding to human IL-23p19 at one or more regions of human IL-23p19 consisting of the amino acid residues selected from the group consisting of residues 93-102, 93-110, and 127-137 of SEQ ID NO:

1.

2. An isolated nucleic acid vector comprising the isolated nucleic acid molecule of claim 1.

3. An isolated host cell comprising the isolated nucleic acid molecule of claim 1, wherein the host cell is prokaryotic or eukaryotic.

4. The isolated host cell of claim 3, wherein said host cell is at least one selected from COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa, myeloma, and lymphoma cells.

5. A method for producing an IL-23p19 antibody, culturing the isolated host cell of claim 4 under conditions such that the IL-23p19 antibody is expressed and recovered.

6. The isolated nucleic acid of claim 1, wherein said antibody is selected from the group consisting of rodent, chimeric, humanized, and human.

7. An isolated nucleic acid molecule encoding an IL-23p19 antibody that competitively binds to IL-23p19 with the isolated IL-23p19 antibody encoded by the nucleic acid molecule of claim 1.

8. An isolated nucleic acid molecule encoding an IL-23p19 antibody, comprising at least one light chain variable region and at least one heavy chain variable region, said light chain variable region nucleotide sequence comprising:

(a) a complementarity determining region light chain 1 (CDRL1) nucleotide sequence encoding the amino acid sequence of SEQ ID NO;

9;

(b) a CDRL2 nucleotide sequence encoding the amino acid sequence of SEQ ID NO;

10; and

(c) a CDRL3 nucleotide sequence encoding the amino acid sequence of SEQ ID NO;

11,

and said heavy chain variable region nucleotide sequence comprising;

(d) a complementarity determining region heavy chain 1 (CDRH1) nucleotide sequence encoding the amino acid sequence of SEQ ID NO;

4;

(e) a CDRH2 nucleotide sequence encoding the amino acid sequence of SEQ ID NO;

5; and

(f) a CDRH3 nucleotide sequence encoding the amino acid sequence of SEQ ID NO;

6.

9. The isolated nucleic acid molecule of claim 8, comprising a nucleotide sequence encoding the light chain variable region amino acid sequence of SEQ ID NO:

8.

10. The isolated nucleic acid molecule of claim 8, comprising a nucleotide sequence encoding the heavy chain variable region amino acid sequence of SEQ ID NO:

3.

11. An isolated nucleic acid molecule, comprising the nucleotide sequence of claim 9 and a nucleotide sequence encoding the heavy chain variable amino acid sequence of SEQ ID NO:

3.

12. An isolated nucleic acid molecule encoding an IL-23p19 antibody that competitively binds to IL-23p19 with the isolated IL-23p19 antibody encoded by the nucleic acid molecule of claim 11.